Showing results (31-40 of 62) with videos related to
Sort By:
Pageof 7
Diabetes Technology & Therapeutics|February 19, 2020
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 TrialSatish K Garg, Karin Wernicke-Panten, Marek Wardecki, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|July 16, 2013
Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-βMeenu Wadhwa, Meena Subramanyam, Susan Goelz, et al.European Journal of Cancer (Oxford, England : 1990)|August 25, 2012
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursSilke Gillessen, Ulrike S Gnad-Vogt, Elisa Gallerani, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 1, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix InsulinS R Aravind, Kiran P Singh, Liliia Mogylnytska, et al.Applied Optics|March 10, 2021
Mitigation of laser-induced contamination in vacuum in high-repetition-rate high-peak-power laser systemsZbyněk Hubka, Jakub Novák, Irena Majerová, et al.Journal of Diabetes Science and Technology|February 29, 2024
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.Diabetes, Obesity & Metabolism|October 26, 2023
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.Journal of Immunological Methods|January 19, 2016
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon betaChristina Hermanrud, Malin Ryner, Thomas Luft, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 14, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)S R Aravind, Kiran P Singh, Grace Aquitania, et al.Frontiers in Neurology|July 22, 2017
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon BetaKathleen Ingenhoven, Daniel Kramer, Poul Erik Jensen, et al.Pageof 7